Table 1: Randomized, Comparative Trials of Oral Therapy for Clostridium difficile Diarrhea
Table 2. Empirical Treatment Strategies for Patients with Multiple
Recurrences of C. difficile Diarrhea
Strategy |
Repeated courses of antimicrobial agents (metronidazole, vancomycin, nitazoxanide, rifaximin) |
Tapering doses of antimicrobial agents (vancomycin, rifaximin) |
Biotherapy Ingestion of bacteria that normally inhabit the bowel (probiotics) Ingestion of non-toxigenic C. difficile Infusion of normal feces (fecal transplantation) |
Monoclonal antibody to C. difficile toxins |
Intravenous immunoglobulin |
Table 3. Potential Future Treatment Options
Product |
Type |
Stage of Development |
Company |
C. difficile vaccine |
Vaccine |
Phase I |
Acambis |
Monoclonal Antibody |
Antibody |
Phase III |
Merck |
Nitazoxanide |
Antibiotic |
Phase III |
Romark |
Ramoplanin |
Antibiotic |
Phase III |
Oscient |
Rifaximin |
Antibiotic |
Phase III |
Salix |
Figure 1: Three Hit Disease